+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

North America Smart Inhalers Market to 2027 - Regional Analysis and Forecasts by Product; End User, and Country

  • PDF Icon

    Report

  • 110 Pages
  • October 2019
  • Region: North America
  • The Insight Partners
  • ID: 4858463
UP TO OFF until Jun 30th 2024
The North America smart inhalers market is expected to reach US$ 3,749.90 Mn in 2027 from US$ 503.91 Mn in 2018. The market is estimated to grow with a CAGR of 25.7% from 2019-2027.

The growth of the smart inhalers market is primarily attributed to the growing geriatric population rising prevalence of COPD and asthma, along with rising awareness regarding the medical condition as well as the presence of supportive associations in the region. However, risks associated with cyber threats with smart inhalers are likely to pose a negative impact on the market growth. On the other hand, development of growth in the North America healthcare market is likely to have a positive impact on the growth of the North America smart inhalers market in the coming years.

The cases of asthma and COPD has been increasing across the globe at a significant rate. During recent years, there has been rise in the number of smokers as well as air pollution in developed as well as developing countries. Asthma is a non-communicable disease categorized by recurrent attacks of breathlessness and wheezing, which differ in severity and frequency from person to person. While an asthma attack occurs, the lining of the bronchial tubes swells, affecting the airways to narrow, hence limiting the flow of air into and out of the lungs. Recurrent asthma symptoms frequently lead to feeling of daytime fatigue, sleeplessness, reduced activity levels and school and work absence. As per estimates provided by the WHO, there are currently 235 million people suffering from asthma across the globe. As per the Centers for Disease Control and Prevention (CDC), the number of adults above 18 years of age currently having asthma are approximately 19 million in the United States, accounting for almost 7.7% of the total adult population.

Similarly, there has been rising prevalence of COPD across the North America. Chronic obstructive pulmonary disease (COPD) is a progressive fatal lung disease that leads to breathlessness, leading to predisposes then exacerbations and later causes serious illness. As per the Global Burden of Disease Study report, a prevalence of around 251 million cases of COPD were recorded globally during the year 2016. It is estimated that globally approximately 3.17 million deaths were caused due to COPD during the year 2015, accounting for almost 5% of all deaths in 2015. The prevalence of COPD has been high in developed nations during the recent years. For instance, COPD is recognized as the third leading cause of death by disease in the United States. Approximately, 11 million individuals are diagnosed with COPD. Hence, the rising prevalence of respiratory conditions such as asthma and COPD is anticipated to fuel the growth of the smart inhalers market across the globe at an exponential rate.

In 2018, the inhalers segment held a largest market share of the smart inhalers market, by product. The inhalers is expected to dominate its market share in 2027 owing to the increasing mortality rate of asthma. The inhalers segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.

Home-care setting segment a largest market share of the smart inhalers market, by end user in 2018. This segment is also expected to dominate the market in 2027. As smart inhaler devices are connected digitally, enabling the patients to get advice from their physicians, even when situated far away. Home-care setting segment is also expected to grow at the fastest growth rate during the forecast period, 2019 to 2027.

Some of the major primary and secondary sources for smart inhalers included in the report are, GlaxoSmithKline plc, Adherium Ltd., Vectura Group plc, Novartis AG, Findair Sp. z o. o., Cohero Health, Crux Product Design Ltd, Teva Pharmaceuticals, 3M, Amiko Digital Health Limited, and others.

Reasons to Buy:
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America smart inhalers market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the North America smarts inhaler Market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth the North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table of Contents

1. Introduction
1.1 Scope Of The Study
1.2 Research Report Guidance
2. North America Smart Inhalers Market - Key Takeaways
3. North America Smart Inhalers Market - Market Landscape
3.1 Overview
3.2 Market Segmentation
3.2.1 North America Smart Inhalers Market - By Product
3.2.2 North America Smart Inhalers Market - By Disorder
3.2.3 North America Smart Inhalers Market - By End User
3.2.4 North America Smart Inhalers Market - By North America Region
3.3 PEST Analysis
4. North America Smart Inhalers Market - Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Increasing Levels of Air Pollution as well as Rise in the Smoking Habits
4.1.2 Rising Prevalence of Asthma and COPD Across the North America
4.1.3 Growing Geriatric Population
4.2 Key Market Restraints
4.2.1 Risks Associated with Cyber Threats
4.2.2 Limited Knowledge Regarding the Use of Smart Inhalers
4.3 Key Market Opportunity
4.3.1 Growth in the North America Healthcare Market
4.4 Future Trend
4.4.1 Increasing Acceptance of Mobile Health Technology
4.5 Impact Analysis
5. Smart Inhalers Market - North America Analysis
5.1 North America Smart Inhalers Market Revenue Forecasts And Analysis
5.2 Performance Of Key Players
6. Smart Inhalers Market Analysis And Forecasts To 2027 - Product
6.1 Overview
6.2 North America Smart Inhalers Market Share By Product 2018 & 2027 (%)
6.3 Inhalers Market
6.3.1 Overview
6.3.2 Inhalers Market Revenue and Forecast to 2027 (US$ Mn)
6.4 Nebulizers Market
6.4.1 Overview
6.4.2 Nebulizers Market Revenue and Forecast to 2027 (US$ Mn)
7. Smart Inhalers Market Analysis And Forecasts To 2027 - Disorder
7.1 Overview
7.2 North America Smart Inhalers Market Share By Application 2018 & 2027 (%)
7.3 Asthma Diabetes
7.3.1 Overview
7.3.2 Asthma Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Chronic Obstructive Pulmonary Disease Market
7.4.1 Overview
7.4.2 Chronic Obstructive Pulmonary Disease Market Revenue and Forecast to 2027 (US$ Mn)
8. Smart Inhalers Market Analysis And Forecasts To 2027 - End User
8.1 Overview
8.2 North America Smart Inhalers Market Share By End User 2018 & 2027 (%)
8.3 Hospitals & Clinics Market
8.3.1 Overview
8.3.2 Hospitals & Clinics Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Home Care Settings Market
8.4.1 Overview
8.4.2 Home-Care Settings Market Revenue and Forecast to 2027 (US$ Mn)
9. Smart Inhalers Market Revenue And Forecasts To 2027 - North America Analysis
9.1 North America Smart Inhalers Market Revenue And Forecasts To 2027
9.1.1 North America Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.2 North America Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.3 North America Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
9.1.4 North America Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.5 North America Smart Inhalers Market Revenue And Forecasts to 2027, By Country (%)
9.1.6 US Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.6.1 US Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.6.2 US Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.6.3 US Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
9.1.6.4 US Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.7 Canada Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.7.1 Canada Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.7.2 Canada Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.7.3 Canada Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
9.1.7.4 Canada Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.8 Mexico Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.8.1 Mexico Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.8.2 Mexico Smart Inhalers Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.8.3 Mexico Smart Inhalers Market Revenue And Forecasts to 2027, By Disorder (US$ Mn)
9.1.8.4 Mexico Smart Inhalers Market Revenue And Forecasts to 2027, By End User (US$ Mn)
10. Smart Inhalers Market- Industry Landscape
10.1 Overview
10.2 Comparative Company Analysis
10.3 Growth Strategies Done By The Companies In The Market, (%)
10.4 Organic Developments
10.4.1 Overview
10.5 Inorganic Developments
10.5.1 Overview
11. Smart Inhalers Market-Key Company Profiles
11.1 Glaxosmithkline Plc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Financial Overview
11.1.4 Product Portfolio
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Adherium Limited
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Financial Overview
11.2.4 Product Portfolio
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Financial Overview
11.3.4 Product Portfolio
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Vectura Group Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Financial Overview
11.4.1 Product Portfolio
11.4.2 SWOT Analysis
11.4.3 Key Developments
11.5 Cohero Health, Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Financial Overview
11.5.4 Product Portfolio
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Crux Product Design Ltd
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Financial Information
11.6.4 Product Portfolio
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Findair Sp. Z O. O.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Financial Overview
11.7.4 Product Portfolio
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Financial Overview
11.8.4 Product Portfolio
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 3M
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Financial Overview
11.9.4 Product Portfolio
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Amiko Digital Health Limited
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Financial Overview
11.10.4 Product Portfolio
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About the Publisher
12.2 Glossary Of Terms

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • GlaxoSmithKline plc
  • Adherium Ltd.
  • Vectura Group plc
  • Novartis AG
  • Findair Sp. z o. o.
  • Cohero Health
  • Crux Product Design Ltd
  • Teva Pharmaceuticals
  • 3M
  • Amiko Digital Health Limited